The official blog of the Lung Institute.

Lung Institute Gives Hope to People

8 Mar 2014
| Under Press | Posted by | 0 Comments

Innovative Stem Cell Treatment at the Lung Institute Gives Lung Disease Patients Another Option

Tampa, Fla. (June 16, 2016) Joseph O. visited the Lung Institute to receive treatment for pulmonary fibrosis, and his positive stem cell treatment results shocked his pulmonologist. When pulmonary fibrosis made Joseph’s life a daily struggle, he knew he had to find another treatment option. On oxygen 24/7, walking up a flight of stairs was a challenge, having a conversation while standing was out of the question, and even brushing his teeth required sitting down. Stem cell therapy from the Lung Institute helped Joseph improve his quality of life.

Joseph started to see improvement about six months after treatment. “My pulmonologist is blown away,” he said. “My oxygen level is steady at 98-99, where it was in the 80s before. I haven’t seen oxygen in over two months. Haven’t touched it. I was on oxygen 24 hours a day, and now, zero.”

Joseph’s doctors’ astonishment at the stem cell treatment’s success is not unusual. They had told him that his disease was terminal and there was not much hope. Many doctors are skeptical of the clinical application of stem cells for lung disease, simply because advancements in the field have been so recent. However, skeptics need only witness the success of pulmonary fibrosis treatments such as Joseph’s to have their position turned upside down.

Joseph’s doctors are not the only ones who have noticed his improvement. “They’ve [Joseph’s family] been jumping up and down,” he said. “I couldn’t go up a flight of steps without having to stop every two or three steps, and now I go all the way up the steps without a problem.”

Before treatment at the Lung Institute, Joseph was diagnosed with pulmonary fibrosis, a deadly lung disease that falls into a larger group of lung diseases called interstitial lung diseases. Pulmonary fibrosis is characterized by the permanent scarring of lung tissue. About 140,000 Americans have been diagnosed with pulmonary fibrosis, typically affecting people ages 50-75. There are a number of potential causes of pulmonary fibrosis, including exposure to airborne toxins, undergoing radiation treatment, genetics and taking some specific medications. However, sometimes doctors are unable to identify a specific cause. When a cause is not found or the disease occurs spontaneously, the disease is called idiopathic pulmonary fibrosis. Approximately 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed each year, claiming the lives of nearly 40,000 people annually.

Because Joseph refused to accept his original lung disease prognosis, he found the courage to try a different treatment option, and now looks forward to the future. “I feel like a million dollars,” he said. Joseph isn’t the only Lung Institute patient who has experienced an improvement in his quality of life after receiving autologous stem cell therapy from the Lung Institute. According to the Lung Institute’s in house white paper, 82 percent of patients studied saw an improvement in their quality of life.

About the Lung Institute

The Lung Institute is a leading medical provider of regenerative cellular therapy for lung diseases such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and interstitial lung disease in the United States. To date the organization has treated over 2,000 patients, 82 percent of which report an improved quality of life. Founded in 2013 in Tampa, Fla., the Lung Institute currently has clinics in Nashville, Tenn.; Scottsdale, Ariz;, Pittsburgh, Pa.; and Dallas, Texas. For more information, please visit www.lunginstitute.com or call (800) 382-8095.

# # #

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.